Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline

All NewsApril 9, 2026

Gilead expands Tempus AI deal and licenses Kymera’s KT-200, advancing oncology pipeline with data, analytics and drug development.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent